Literature DB >> 12016021

High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard.

Anjaneya P Chimalakonda1, Rakhi B Shah, Reza Mehvar.   

Abstract

All the available HPLC assays of cyclosporin A (CyA) use internal standards that are not commercially available. Our purpose was to develop an HPLC assay for measurements of CyA in rat blood and liver using a commercially available internal standard (I.S.). After the addition of tamoxifen (I.S.), blood (0.25 ml) or the liver homogenate (1 ml) samples were extracted into a mixture of ether:methanol (95:5). The residue after evaporation of the organic layer was dissolved in 200 microl of an injection solution and washed with 1 ml of hexane before analysis. The separation was achieved using an LC-1 column (70 degrees C) with a mobile phase of methanol-acetonitrile-0.01 M KH(2)PO(4) (50:25:25, v/v) and a flow-rate of 1 ml/min. Detection was at 205 nm. Cyclosporin A and I.S. eluted at 5 and 7 min, respectively, free from endogenous peaks. Linear relationships (r>0.98) were observed between the CyA:I.S. peak area ratios and the CyA concentrations within the range of 0.2-10 microg/ml for blood and 0.1-4 microg/ml for the liver homogenates. The intra- and inter-run C.V.s and errors for both the blood and liver samples were <15%. The extraction efficiency (n=5) was close to 100% for both CyA and I.S. in both blood and liver homogenates. The lower limit of quantitation of the assay was 0.2 or 0.1 microg/ml based on 250 microl of blood or 1 ml of liver homogenate, respectively. The assay was capable of measuring blood and liver concentrations of CyA in a rat injected intravenously with a single 5-mg/kg dose of the drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12016021     DOI: 10.1016/s1570-0232(02)00062-4

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function.

Authors:  Hamidreza Montazeri Aliabadi; Tara J Spencer; Parvin Mahdipoor; Afsaneh Lavasanifar; Dion R Brocks
Journal:  AAPS J       Date:  2006-10-27       Impact factor: 4.009

2.  Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles.

Authors:  Jie Lai; Yi Lu; Zongning Yin; Fuqiang Hu; Wei Wu
Journal:  Int J Nanomedicine       Date:  2010-02-02

3.  Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles.

Authors:  Ling Zhang; Zhi-Liang Zhao; Xiao-Hong Wei; Jin-Hua Liu
Journal:  Int J Nanomedicine       Date:  2013-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.